Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

There are many new advances in neuroscience and mental health which should lead to a greater understanding of the neurobiological dysfunction in neuropsychiatric disorders and new developments for early, effective treatments. To do this, a biomarker approach combining genetic, neuroimaging, cognitive and other biological measures is needed. The aim of this article is to highlight novel approaches for pharmacological and non-pharmacological treatment development. This article suggests approaches that can be taken in the future including novel mechanisms with preliminary clinical validation to provide a toolbox for mechanistic studies and also examples of translation and back-translation. The review also emphasizes the need for clinician-scientists to be trained in a novel way in order to equip them with the conceptual and experimental techniques required, and emphasizes the need for private-public partnership and pre-competitive knowledge exchange. This should lead the way for important new holistic treatment developments to improve cognition, functional outcome and well-being of people with neuropsychiatric disorders.

Original publication

DOI

10.1016/j.neubiorev.2013.03.022

Type

Journal article

Journal

Neurosci Biobehav Rev

Publication Date

12/2013

Volume

37

Pages

2438 - 2444

Keywords

Back-translation, Biomarkers, Cognitive and psychosocial treatments, Neurobiological mechanisms, Neuropsychiatric disorders, Novel drug development, Pharmacological tool box, Translation, Animals, Biomarkers, Brain, Drug Discovery, Early Medical Intervention, Humans, Mental Disorders, Molecular Targeted Therapy, Research Support as Topic